Bookmark
Forward
QuickView for Dobutamine (compound)
PubChem
| Name: | Dobutamine |
|---|---|
| PubChem Compound ID: | 208850 |
| Description: | A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. |
| Molecular formula: | C22H29NO9 |
| Molecular weight: | 451.467 g/mol |
| Synonyms: |
LY 174008; Dobutamine tartrate; 101626-66-8; 1,2-Benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (- )-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt); Dobutamine tartrate [USAN]; Dobutamine tartrate (USP); D03881
|
DrugBank
Identification
| Name: | Dobutamine |
|---|---|
| Name (isomeric): | DB00841 |
| Drug Type: | small molecule |
| Description: | A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. |
| Brand: | Dobutrex, Dobutamine [Usan:Ban:Inn], Dobutamine Hcl, Dobutamine [Usan], Racemic-Dobutamine, Inotrex, Dobutaminum [INN-Latin], Dobutamina [INN-Spanish], Dobutamine Hydrochloride, Dobutamine Hcl in Dextrose 5% |
| Category: | Sympathomimetic, Adrenergic beta-Agonists, Cardiotonic Agents, Sympathomimetics |
| CAS number: | 34368-04-2 |
Pharmacology
| Indication: | For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures |
|---|---|
| Pharmacology: |
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It do...
show more » |
| Mechanism of Action: | Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. |
| Route of elimination: | In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. |
| Half Life: | 2 minutes |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
